RE: US$400m Wow !8 Jan 2024 13:40
Recent Developments
Last Updated: 03/01/2024
C4XD announced a significant ($11m) milestone payment from AstraZeneca on 3 January, under a licensing deal with Astra Zeneca, signed in November 2022. Under the agreement, AstraZeneca received an exclusive global licence for the NRF2 Activator programme. In return, C4XD received a $2m upfront payment and is eligible for pre-clinical milestone payments totalling $14m and a further $386m in clinical and commercial milestone payments. AstraZeneca are developing the drug as a treatment for a number of inflammatory conditions and the market for these is worth $60bn. The category includes Sickle Cell Disease, IBD and lung diseases such as COPD. We shall be meeting the CEO later in January.